Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Malignant tumors exhibit immunotolerance, evading immune surveillance and leading to progression and therapeutic resistance.
• Interleukin-6 (IL-6), a pro-inflammatory cytokine, is implicated in numerous physiological and pathological processes.
• Aberrant IL-6 expression correlates with cancer growth, metastasis, and chemotherapeutic resistance.

Purpose of the Study:

• To review IL-6 signaling pathways in cancer.
• To summarize molecular mechanisms of IL-6-induced immunosuppression in tumors.
• To discuss clinical studies targeting IL-6 for cancer immunotherapy.

Main Methods:

• Literature review of IL-6 pathways and function in cancer.
• Analysis of molecular mechanisms underlying IL-6-mediated immunosuppression.
• Summary of recent clinical trials targeting IL-6.

Main Results:

• IL-6 promotes tumor immune evasion by recruiting myeloid-derived suppressor cells, tumor-associated neutrophils, and cancer stem cells.
• The Janus-activated kinase/signal transducer and activator of transcription 3 (JAK/STAT3) pathway is crucial for IL-6-induced immunosuppression.
• Targeting IL-6 has shown potential in preclinical and clinical settings for cancer treatment.

Conclusions:

• IL-6 plays a significant role in establishing an immunosuppressive tumor microenvironment.
• Inhibition of IL-6 signaling presents a viable therapeutic avenue for enhancing anti-tumor immunity.
• Further clinical investigation of IL-6 targeted therapies is warranted for various cancers.